2. Vitamin D Related/Nuclear Receptor
  3. Progesterone Receptor
  4. Medroxyprogesterone

Medroxyprogesterone  (Synonyms: 17α-Hydroxy-6α-methylprogesterone; U8840)

Cat. No.: HY-B0648 Purity: 99.30%
COA Handling Instructions

Molarity Calculator

Medroxyprogesterone (17α-Hydroxy-6α-methylprogesterone) is a synthetic human variant of progesterone that is a progesterone receptor agonist with oral activity. Medroxyprogesterone can induce cell proliferation through the PI3K/Akt signaling pathway. Medroxyprogesterone has an inhibitory effect on atherosclerosis in mice. The progesterone agonist activity of Medroxyprogesterone is less effective than Medroxyprogesterone acetate (HY-B0469).

For research use only. We do not sell to patients.

Medroxyprogesterone Chemical Structure

Medroxyprogesterone Chemical Structure

CAS No. : 520-85-4

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 66 In-stock
Solution
10 mM * 1 mL in DMSO USD 66 In-stock
Solid
100 mg USD 60 In-stock
500 mg USD 180 In-stock
1 g USD 240 In-stock
5 g   Get quote  
10 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 8 publication(s) in Google Scholar

Other Forms of Medroxyprogesterone:

Medroxyprogesterone Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Medroxyprogesterone (17α-Hydroxy-6α-methylprogesterone) is a synthetic human variant of progesterone that is a progesterone receptor agonist with oral activity. Medroxyprogesterone can induce cell proliferation through the PI3K/Akt signaling pathway. Medroxyprogesterone has an inhibitory effect on atherosclerosis in mice. The progesterone agonist activity of Medroxyprogesterone is less effective than Medroxyprogesterone acetate (HY-B0469)[1][2][3][4].

In Vitro

Medroxyprogesterone (10 nM, 48 h) has induced Cyclin D1 expression through the PI3K/Akt signaling pathway to promote cell proliferation in T47D cells [1].
Medroxyprogesterone (100 nM, 24 h) has increased the number of monocytes adhering to HUVECs by increasing the expression of adhesion molecules in HUVEC cells, which may be the cause of atherosclerosis[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Medroxyprogesterone Related Antibodies

Cell Proliferation Assay[1]

Cell Line: T47D
Concentration: 10 nM
Incubation Time: 24 h, 48 h, 72h
Result: Increased the number of cells at 48 h.

Western Blot Analysis[1]

Cell Line: T47D
Concentration: 10 nM
Incubation Time: 4 h
Result: Induced the expression of Cyclin D1 protein.

RT-PCR[2]

Cell Line: HUVECs
Concentration: 100 nM
Incubation Time: 24 h
Result: Increased mRNA and protein expression of adhesion molecules.
In Vivo

Medroxyprogesterone (27.7 μg/ day, injected subcutaneously) has an inhibitory effect on arteriosclerosis in mice but can increase thrombosis [3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: ApoE-/- mice model[3]
Dosage: 27.7 μg/day
Administration: s.c.
Result: Reduced atherosclerotic plaque and increased thrombosis.
Clinical Trial
Molecular Weight

344.49

Formula

C22H32O3
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

C[C@@]1([C@@]2(O)C(C)=O)[C@](CC2)([H])[C@@](C[C@H](C)C3=CC4=O)([H])[C@]([C@]3(CC4)C)([H])CC1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : 50 mg/mL (145.14 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.9028 mL 14.5142 mL 29.0284 mL
5 mM 0.5806 mL 2.9028 mL 5.8057 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (7.26 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.30%

COA (252 KB) LCMS (108 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.9028 mL 14.5142 mL 29.0284 mL 72.5710 mL
5 mM 0.5806 mL 2.9028 mL 5.8057 mL 14.5142 mL
10 mM 0.2903 mL 1.4514 mL 2.9028 mL 7.2571 mL
15 mM 0.1935 mL 0.9676 mL 1.9352 mL 4.8381 mL
20 mM 0.1451 mL 0.7257 mL 1.4514 mL 3.6286 mL
25 mM 0.1161 mL 0.5806 mL 1.1611 mL 2.9028 mL
30 mM 0.0968 mL 0.4838 mL 0.9676 mL 2.4190 mL
40 mM 0.0726 mL 0.3629 mL 0.7257 mL 1.8143 mL
50 mM 0.0581 mL 0.2903 mL 0.5806 mL 1.4514 mL
60 mM 0.0484 mL 0.2419 mL 0.4838 mL 1.2095 mL
80 mM 0.0363 mL 0.1814 mL 0.3629 mL 0.9071 mL
100 mM 0.0290 mL 0.1451 mL 0.2903 mL 0.7257 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Medroxyprogesterone Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Medroxyprogesterone520-85-417α-Hydroxy-6α-methylprogesterone U8840U8840U 8840U-8840Progesterone ReceptorNR3C3Progesterone Receptor AgonistT47D cellsHUVECsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Medroxyprogesterone
Cat. No.:
HY-B0648
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.